A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
Status:
Completed
Trial end date:
2018-04-11
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies fludeoxyglucose F18 (FDG)-positron emission tomography
(PET) in imaging patients with prostate cancer treated with ranolazine. Diagnostic
procedures, such as FDG-PET, may help find prostate cancer and find out how far the disease
has spread. Giving ranolazine may enhance FDG-PET imaging by increasing the amount of glucose
available for uptake by the scan.